Dónal Landers is Clinical Leader for the iDecide programme at The Cancer Research UK Manchester Institute, a world-leading centre for excellence in cancer research.
Dónal obtained his primary medical degree from Trinity College, Dublin. He has an MBA from University College Dublin, and studied Computer Science at Dublin City University. He has a certificate in Translational Medicine from the University of Manchester and is a Member of the Faculty of Pharmaceutical Medicine where he has completed his higher medical training in this specialty. He is a Senior Director Physician with AstraZeneca and leads a large global study, primarily in bladder cancer in Early Clinical Development (ECD) combining immune checkpoint inhibitors and targeted therapies.
: Design, implementation and launch of the first AZ sponsored ‘umbrella’ study in bladder cancer
BISCAY: An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi‑Centre, Multi‑arm Phase 1b Study in patients with Muscle Invasive Bladder Cancer (MIBC) who have progressed on prior treatment (BISCAY). This study is highly agile, adaptive and enables additional combinations to be added quickly to new arms.
Clinical Leader iDecide Programme
iDecide is a 5-year collaboration between four strategic partners/leaders in oncology research; the University of Manchester Institute of Cancer Sciences, the Centre for Cancer Biomarker Sciences, Christie NHS Foundation Trust the clinical trials unit, and AstraZeneca.
Real-time Analytics of Clinical Trials (REACT) won the prestigious Clinical and Health IT best practice award at the tenth annual BIO-IT awards in Boston, USA
REACT has transformed the process for reviewing patient information during an ongoing clinical trial, within AstraZeneca’s Early and Late Stage clinical portfolio.
Safety, Tolerability and Pharmacokinetics of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Japanese Patients with Advanced Solid Tumours: a Phase I Study.
Investigational New Drugs. 2017
Erratum to: Development and Evaluation of a New Technological Way of Engaging Patients and Enhancing Understanding of Drug Tolerability in Early Clinical Development:
PROACT. Advances in Therapy. 2016, Sep. 33(9): 1677–1678
BISCAY, a Phase Ib, Biomarker-Directed Multidrug Umbrella Study in Patients with Metastatic Bladder Cancer.
Clin Oncol 34, 2016 (suppl; abstr TPS4577)
FIESTA: A Phase Ib and Pharmacokinetic Trial of AZD4547 in Combination with Gemcitabine and Cisplatin.
J Clin Oncol 34, 2016 (suppl; abstr 4521)
Development and Evaluation of a New Technological Way of Engaging Patients and Enhancing Understanding of Drug Tolerability in Early Clinical Development:
PROACT. Advances in Therapy. 2016 Jun;33(6):1012-24
Complexity of FGFR Signalling in Metastatic Urothelial Cancer.
Journal of Hematology & Oncology. 2015. Oct; 8:119
PROACT: A New Way of Engaging And Empowering Patients That Fundamentally Changes our Understanding of Tolerability Impacts in Early Clinical Development.
Eur J Cancer. 2015, 51 S138-S138
A Randomized, Open-Label Phase II Study of AZD4547 Versus Paclitaxel in Previously Treated Patients with Advanced Gastric Cancer (AGC) with Fibroblast Growth Factor Receptor 2 (FGFR2) Polysomy or Gene Amplification:
SHINE Study. J Clin Oncol 33, 2015 (suppl; abstr 4014)
A Multi-Centre, Single Arm, Open Label Phase Ib Study to Assess the Safety and Efficacy Of AZD4547 in Combination with Either Anastrozole or Letrozole in ER Positive Breast Cancer Patients who have Progressed on Treatment with Anastrozole or Letrozole (RADICAL) - Safety Run-in Results.
2014 NCRI Cancer Conference. Abstract A139
Abstract LB-146: A Phase II Randomized Placebo-Controlled Study of AZD8931, an Inhibitor of EGFR, HER2, and HER3 Signaling, plus Paclitaxel (P) Vs P Alone in Patients (Pts) with Low HER2-Expressing Advanced Breast Cancer (BC) (THYME).
AACR; Cancer Res 2013;73(8 Suppl):Abstract nr LB-146
Phase II Randomized Study of AZD8931 in Combination with Anastrozole (A) in Women with Endocrine-Therapy-Naive Advanced Breast Cancer (MINT).
J Clin Oncol 31, 2013 (suppl; abstr 531)
An Extranet Architecture for Inter-Operability Among Healthcare Systems.
Health Informatics Journal (2000) 6, 228-235
Faculty of Pharmaceutical Medicine – Completion of Postgraduate Specialist Training (JRCPTB) in Pharmaceutical Medicine and entry to the GMC Specialist Register 2016
Real-time Analytics of Clinical Trials (REACT) winner IT best practice award for Clinical & Health IT 10th annual BIO-IT awards
IMED Science Awards 2013 – Recognition Award – Development of the REACT System
In everything we do, all paths should lead to the patient
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.